聚焦超声刺激微泡增强头颈癌放疗:一项1期临床试验
这项前瞻性1期临床试验评估MR引导聚焦超声刺激微泡(MRgFUS-MB)联合放疗治疗头颈癌的安全性与疗效。11例可评估患者中无全身毒性或MRgFUS-MB相关不良事件,最严重急性不良事件为6例(55%)发生放射性3级毒性;3个月肿瘤反应评估的8例中4例部分缓解、3例完全缓解、1例进展。作者结论为MRgFUS-MB治疗安全且与3个月高肿瘤缓解率相关。
要点
- 11例安全分析患者中无全身毒性或MRgFUS-MB相关不良事件发生。
- 最严重急性不良事件为放射性3级毒性,6例(55%)发生。
- 3个月肿瘤反应可评估8例:部分缓解4例(50%)、完全缓解3例(37.5%)、进展1例(12.5%)。
核心结论
- 作者结论为MRgFUS-MB治疗安全,并与3个月高肿瘤缓解率相关。
研究设计与样本
- 前瞻性1期临床试验,纳入新诊断或复发头颈癌患者(除外鼻咽部恶性肿瘤),适合根治性或姑息性局部区域放疗。
- 排除微泡给药或对比增强MR禁忌者;2020年6月至2023年11月入组12例,1例撤回知情同意,11例纳入安全性分析。
- 接受5-10次和33-35次放疗分次的患者分别计划接受2次和3次MRgFUS-MB治疗。
- 主要终点为CTCAEv5.0毒性,次要终点为3个月时按RECIST 1.1评估的肿瘤反应。
主要发现
- 中位随访7个月(范围0.3-38);多数为口咽癌(55%),63%接受20-30 Gy/5-10次放疗。
- 无全身毒性或MRgFUS-MB相关不良事件发生;最严重急性不良事件为放射性3级毒性,6例(55%)发生(皮炎3例、黏膜炎1例、吞咽困难6例)。
- 无放射性坏死或4/5级毒性报告。
- 8例纳入3个月肿瘤反应评估:部分缓解4例(50%)、完全缓解3例(37.5%)、进展1例(12.5%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Preclinical research demonstrated that the exposure of microbubbles (intravascular gas microspheres) to focussed ultrasound within the targeted tumour upregulates pro-apoptotic pathways and enhances radiation-induced tumour cell death. This study aimed to assess the safety and efficacy of magnetic resonance (MR)-guided focussed ultrasound-stimulated microbubbles (MRgFUS-MB) for head and neck cancers (HN). MATERIALS AND METHODS: This prospective phase 1 clinical trial included patients with newly diagnosed or recurrent HN cancer (except nasopharynx malignancies) for whom locoregional radiotherapy with radical- or palliative-intent as deemed appropriate. Patients with contraindications for microbubble administration or contrast-enhanced MR were excluded. MR-coupled focussed ultrasound sonicated intravenously administered microbubbles within the MR-guided target volume. Patients receiving 5-10 and 33-35 radiation fractions were planned for 2 and 3 MRgFUS-MB treatments, respectively. Primary endpoint was toxicity per CTCAEv5.0. Secondary endpoint was tumour response at 3 months per RECIST 1.1 criteria. RESULTS: Twelve patients were enrolled between Jun/2020 and Nov/2023, but 1 withdrew consent. Eleven patients were included in safety analysis. Median follow-up was 7 months (range, 0.3-38). Most patients had oropharyngeal cancer (55 %) and received 20-30 Gy/5-10 fractions (63 %). No systemic toxicity or MRgFUS-MB-related adverse events occurred. The most severe acute adverse events were radiation-related grade 3 toxicities in 6 patients (55 %; dermatitis in 3, mucositis in 1, dysphagia in 6). No radiation necrosis or grade 4/5 toxicities were reported. 8 patients were included in the 3-month tumour response assessment: 4 had partial response (50 %), 3 had complete response (37.5 %), and 1 had progressive disease (12.5 %). CONCLUSIONS: MRgFUS-MB treatment was safe and associated with high rates of tumour response at 3 months.
引用
- Moore-Palhares D, Saifuddin M, Dasgupta A, et al. Radiation enhancement using focussed ultrasound-stimulated microbubbles for head and neck cancer: A phase 1 clinical trial. Radiother Oncol. 2024. PMID: 38879128. doi:10.1016/j.radonc.2024.110380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。